COMPASS Pathways plc (ticker: CMPS) recently announced that its innovative therapy Comp360 psilocybin for treatment-resistant depression has successfully achieved the primary endpoint in the second pivotal Phase 3 clinical trial.
Show original
This groundbreaking development marks a solid step forward in validating the safety and efficacy of this therapy, bringing new hope to millions of patients worldwide suffering from treatment-resistant depression.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Intesa Sanpaolo discloses $96 million Bitcoin ETF holdings
AIcoin•2026/02/17 12:52
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$68,090.17
-1.90%
Ethereum
ETH
$1,984.41
-0.87%
Tether USDt
USDT
$0.9997
+0.01%
XRP
XRP
$1.46
-3.18%
BNB
BNB
$621.49
-0.78%
USDC
USDC
$1
-0.01%
Solana
SOL
$84.89
-1.31%
TRON
TRX
$0.2812
+0.02%
Dogecoin
DOGE
$0.1000
-1.99%
Bitcoin Cash
BCH
$562.44
-0.94%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now